Suspension of trading

News Durect

Stocks

DRRX

US2666055007

Market Closed - Nasdaq 00:00:00 11/09/2025 +04			5-day change	1st Jan Change
1.910 ^USD	-1.04%		-.--%	-

11/09/25	Bausch Health Companies Inc. completed the acquisition of DURECT Corporation.	CI
11/09/25	Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline	MT

All News

Mentions Relevance

11/09/25	Bausch Health Companies Inc. completed the acquisition of DURECT Corporation.	CI
11/09/25	Durect Corporation Announces Board Changes	CI
11/09/25	Bausch Health Completes $63 Million Acquisition of Durect	MT
11/09/25	DURECT Corporation(NasdaqCM:DRRX) dropped from S&P TMI Index	CI
11/09/25	DURECT Corporation(NasdaqCM:DRRX) dropped from NASDAQ Composite Index	CI
26/08/25	Bausch Health Extends Tender Offer for DURECT Shares to Sept. 10	MT
22/08/25	Durect Insider Bought Shares Worth $386,666, According to a Recent SEC Filing	MT
13/08/25	Durect: Q2 Earnings Snapshot	AQ
13/08/25	DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health	PR
13/08/25	DURECT Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/08/25	Durect Bausch Health extend tender offer date to Aug 12 - SEC filing	RE
29/07/25	Northland Downgrades DURECT to Market Perform From Outperform, Price Target is $2.50	MT
29/07/25	Bausch Health to Acquire Durect for $63 Million	MT
15/05/25	Durect: Q1 Earnings Snapshot	AQ
14/05/25	DURECT Corporation Reports First Quarter 2025 Financial Results And Provides Business Update	RE
14/05/25	DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update	PR
14/05/25	DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/03/25	DURECT Corporation Auditor Raises 'Going Concern' Doubt	CI
27/03/25	DURECT Corporation, Q4 2024 Earnings Call, Mar 26, 2025
27/03/25	Durect: Q4 Earnings Snapshot	AQ
27/03/25	DURECT Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
20/03/25	DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update	PR
22/02/25	DURECT Corporation Announces Retirement of Terrence F. Blaschke as Board of Director, Member of the Nominating and Corporate Governance Committee	CI
04/02/25	DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
28/01/25	DURECT Corporation Announces Publication of Larsucosterol Phase 2B Results in NEJM Evidence	CI